GlucoTrack, Inc. (GCTK)
NASDAQ: GCTK · Real-Time Price · USD
0.8873
-0.2227 (-20.06%)
At close: Oct 14, 2026, 4:00 PM EDT
0.8701
-0.0172 (-1.94%)
After-hours: Oct 14, 2026, 4:17 PM EDT
GlucoTrack Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
15
Market Cap
725.03K
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | 208.00K | 164.51K | 378.29% |
| Dec 31, 2018 | 43.49K | -545.97K | -92.62% |
| Dec 31, 2017 | 589.46K | -22.23K | -3.63% |
| Dec 31, 2016 | 611.69K | 468.52K | 327.26% |
| Dec 31, 2015 | 143.17K | 83.39K | 139.51% |
| Dec 31, 2014 | 59.78K | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
| Dec 31, 2010 | - | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Vivos Therapeutics | 20.90M |
| WORK Medical Technology Group LTD | 10.72M |
| Nuwellis | 9.01M |
| Beyond Air | 7.69M |
| INVO Fertility | 7.53M |
| Tenon Medical | 5.31M |
| VolitionRx | 2.46M |
| Nexalin Technology | 217.16K |
GCTK News
- 7 hours ago - GlucoTrack subsidiary announces public launch of Qare - TheFly
- 8 hours ago - GlucoTrack Registration statement: Registration filing - Filings
- 1 day ago - GlucoTrack Proxy statement: Proxy filing - Filings
- 20 days ago - GlucoTrack prices 169,388 shares at $2.04 in public offering - TheFly
- 20 days ago - Glucotrack, Inc. Announces Pricing of $3 Million Public Offering - Business Wire
- 21 days ago - Lōkahi Therapeutics™ and Glucotrack CEO Erik Emerson Provides Strategic Update on LT-100, ai² Platform Growth and Clinical Development Priorities - Business Wire
- 26 days ago - GlucoTrack Registration statement: Registration filing - Filings
- 26 days ago - GlucoTrack files to sell 43.45M shares of common stock for holders - TheFly